Birch Pollen AllergyPhase 1NCT01628484
Physiological Study to Determine the Allergic Skin Activity After Different Skin Preparation
A Phase 1 study testing prick lancet, Tape stripping and Microneedle in people with Birch Pollen Allergy, run by University of Zurich at 1 site in Switzerland.
Trial summary
The objectives of this monocentric investigator initiated exploratory clinical trial is to optimize allergen delivery across the epidermal barrier. The cornified outer epidermal layers represent the main barrier towards entry into the viable epidermal layers. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Birch Pollen Allergy
- What is being tested?
- prick lancet, Tape stripping and Microneedle
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteSwitzerland
- Study dates
- Jul 2012to Sep 2012
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Written informed consent
- 18-65 years old (male and female)
- A positive clinical history for inhalant allergy presumably due to birch pollen
- Positive screening prick test (mean wheal diameter = 3mm) to birch pollen allergen solution
- A mean wheal size of = 7mm2 obtained in the screening prick test with histamine dihydrochloride (10mg/ml)
Who cannot join
- Impaired in understanding the nature, meaning and scope of the study or incapable of giving written informed consent
- Participation in another clinical trial within the last 30 days and during the present study
- Pregnancy or nursing
- Positive skin reaction in the screening prick test to NaCl
- Currently suffering from allergy symptoms
- History of systemic reactions to allergens
Show all 11Show fewer
- Severe diseases influencing the results of the present study by discretion of the investigator
- Immunotherapy with the allergen preparation during the past two years
- Skin lesions and excessive hair-growth in the skin test areas
- Treatment with prohibited concomitant medications, with the exception of medications with local effects which will not influence the results of the skin prick tests
- Alcohol or drug abuse
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University Hospital Zurich, Division of Dermatology
Zurich, Canton of Zurich, 8091
About this study
Official title: Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutaneous Allergen Exposure
The objectives of this monocentric investigator initiated exploratory clinical trial is to optimize allergen delivery across the epidermal barrier. The cornified outer epidermal layers represent the main barrier towards entry into the viable epidermal layers. In the latter we aim to target the allergen for uptake by professional antigen presenting cells, called Langerhans cells. At the same time as little allergen as possible should be delivered to the dermis. The latter contains a high density of sensitized mast cells eliciting local reactions and also a high density of blood vessels which could lead to systemic distribution of allergen and therefore to systemic allergic reactions.
In birch pollen allergic individuals we will compare different methods of preparing the skin before application of the allergen. We will subsequently apply titrated allergen doses to the prepared skin areas to determine at which dose we start observing mast cell degranulation manifesting as hives.
Read more
This will allow for determination of the maximal tolerated allergen dose for each skin preparation method.
The skin preparation methods compared will be:
- Single pricking with prick lancet (Entaco LTD., Redditch, Worcestershire, UK, distributed by Stallergenes®).
- Tape stripping with conventional adhesive Tape (Tesa-film®).
- Microchanneling with Micro Needle Patch (Micro Skin System, 3M®). The methods are strongly connected to routine diagnostics of allergies with low risk associated.
The clinical trial protocol has been submitted to the local Ethics Committee.
This comparison of skin preparation methods and the determination of the maximal tolerated allergen dose will help us to further improve epicutaneous allergen immunotherapy, which has the potential to make allergen specific immunotherapy not only considerably shorter and safer, but also more convenient for patients. Skin preparation by microneedle patches is significantly less painful than conventional injection and can be self administered. This should help improve the acceptance of allergen specific immunotherapy, as well as treatment compliance.
Read the detailed description
BACKGROUND INFORMATION The prevalence of allergic diseases has been continuously increasing, reaching a prevalence of up to 30% in industrialized countries. In Switzerland, about 2 million people are affected by IgE-mediated allergies as reported by the Swiss Center for Allergy, Skin and Asthma and the Swiss Society for Allergology and Immunology (SSAI). By subcutaneous injections of gradually increasing allergen doses, conventional subcutaneous SIT (SCIT) is found to reduce the inappropriate T-helper (Th) 2 responses and IgE production. Due to the risk of systemic allergic side effects, the typical therapy duration of 3-5 years and the requirement of 50-80 injections, patient acceptance of SCIT is low and less than 5% of allergy patients choose to undergo SCIT. A recently rediscovered route of allergen administration is via the epidermis in a procedure called epicutaneous immunotherapy (EPIT).
The skin is an attractive administration route for immunotherapy being both easily accessible as well as playing an important role in the immune system consisting of keratinocytes, Langerhans cells (LC), dermal dendritic cells (DC). A major challenge in EPIT is to overcome the physiological barrier function of the skin. In order to deliver the allergen to the immunological effector cells in the skin, the allergen must be transported through the outermost keratinized layer of the epidermis, called the stratum corneum. The stratum corneum is 10-20μm thick and impermeable for molecules greater than 500 Da. Proteins, such as allergens, do not passively permeate across the skin and therefore enhancement strategies are needed to enable this transfer. Advances in microtechnology might contribute to improve the situation by allowing for the miniaturization of mechanics and structures. As the stratum corneum is only 10-20μm thick, it has been proposed by Henry et al., that microneedles as small as a few tens to a few hundreds of microns, could be used to penetrate the stratum corneum.
Such new methods of overcoming the skin barrier raise the question of the influence of different types of skin injury patterns on the allergic skin reactivity. Namely, how important is the role of the exposed area (microneedles), the depth of injury (skin pricking) and the keratinocyte activation. This physiological question is in the focus of this study.
PRODUCTS In order to investigate the physiological reactions concerning different skin conditions and allergen exposition the following products/techniques have been chosen for the purpose of inducing different skin conditions in a reproducible way.
Prick lancet:
For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used: prick lancet, produced by Entaco LTD., Redditch, Worcestershire, UK and distributed by Stallergenes®. They are used for allergy diagnostics in daily routine.
Adhesive tape:
For the tape stripping skin preparation a conventional tape will be used (Tesafilm®).
Microneedle array:
To induce a large number of microchannels with a maximal depth of 150μm into the cornea layer,the solid Microstructured Transdermal System (sMTS) by 3M® will be used. This system is a small patch of 351 tiny needles, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
Epicutaneous allergen solution:
For the epicutaneous administration four ten-fold serial dilutions (10 HEP, 1 HEP, 0.1 HEP and 0.01HEP/ml) of registered allergen extracts of birch pollen (Betula verrucosa) (Soluprick®, ALK-Abelló A/S, Hørsholm, Denmark) will be used as in everyday allergy diagnostic practice. Histamine as positive control will be used at 10 mg/ml and a solution containing only the excipients will serve as negative control.
This is an open-label physiological investigation of the allergic skin reactivity to epicutaneous allergen exposition in allergic patients comparing different methods of skin preparation. The focus of the study is on the skin preparation and not on the specific allergen or allergy, but for reasons of homogeneity a single allergic disease, birch pollen allergy was chosen as the basis for the testing. In order to evaluate the effects of the different skin preparation techniques an intra-individual comparison of the skin reactivity in terms of the immediate phase I reaction to serial dilutions of birch pollen extracts was chosen. The serial dilution approach allows a dose dependent effect evaluation and determination of the mean allergen concentration yielding similar skin reactions - thus differences will be explained mainly by the different skin preparation allowing a quantitative comparison of these techniques.
HYPOTHESIS We will determine which of the three different skin preparation techniques uses higher protein concentration of allergen preparation (Ch10) eliciting a wheal area of the same size as histamine 10 mg/ml will be calculated.
The Null hypothesis therefore would be:
Ch10 is not significantly different between the three skin preparation techniques.
- Conditions
- Birch Pollen Allergy
- Being tested
- prick lancet, Tape stripping, Microneedle
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
prick lancetOther
Also called Prick Lancet; Worcestershire, UK; distr. by Stallergenes®.
For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine.
Tape strippingOther
Also called Tesafilm
For the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used.
MicroneedleOther
Also called solid Microstructured Transdermal System (sMTS) by 3M®
To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
| Study group | Role | What they receive |
|---|---|---|
| Skin Preparation Testing | Other | The methodology of this study is an intra-individual comparison. Each study participant is treated with three skin preparation techniques (pricking, tape stripping, microneedle array)on both volar forearms. Receives: Other: prick lancet; Other: Tape stripping; Other: Microneedle |
What is being measured
The primary outcome is the main question the study is designed to answer.
Wheal size of the immediate reaction in mm2.
Measured: 15 minutes
Secondary outcomes (1)
Late phase response.
Evaluation of late phase reaction (eczema development).
Measured: 3 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2012 (estimated)
- Study startJul 2012
- Primary completionSep 2012
- Study completionSep 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Birch Pollen AllergyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Thomas Kuendig, MD, Principal investigator, University Hospital Zurich, Division of Dermatology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01628484
- Sponsor's protocol ID
- SkinPrep
- Status last verified
- Nov 2012
- First submitted
- 22 Jun 2012
- Last updated
- 7 Nov 2012
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Nov 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutaneous Allergen Exposure
- ClinicalTrials.gov ID
- NCT01628484
- Acronym / sponsor ID
- SkinPrep
- Conditions
- Birch Pollen Allergy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Study start
- Jul 2012
- Primary completion
- Sep 2012 (actual)
- Study completion
- Sep 2012 (actual)
- First posted
- 26 Jun 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objectives of this monocentric investigator initiated exploratory clinical trial is to optimize allergen delivery across the epidermal barrier. The cornified outer epidermal layers represent the main barrier towards entry into the viable epidermal layers. In the latter we aim to target the allergen for uptake by professional antigen presenting cells, called Langerhans cells. At the same time as little allergen as possible should be delivered to the dermis. The latter contains a high density of sensitized mast cells eliciting local reactions and also a high density of blood vessels which could lead to systemic distribution of allergen and therefore to systemic allergic reactions.
In birch pollen allergic individuals we will compare different methods of preparing the skin before application of the allergen. We will subsequently apply titrated allergen doses to the prepared skin areas to determine at which dose we start observing mast cell degranulation manifesting as hives.
This will allow for determination of the maximal tolerated allergen dose for each skin preparation method.
The skin preparation methods compared will be:
- Single pricking with prick lancet (Entaco LTD., Redditch, Worcestershire, UK, distributed by Stallergenes®).
- Tape stripping with conventional adhesive Tape (Tesa-film®).
- Microchanneling with Micro Needle Patch (Micro Skin System, 3M®). The methods are strongly connected to routine diagnostics of allergies with low risk associated.
The clinical trial protocol has been submitted to the local Ethics Committee.
This comparison of skin preparation methods and the determination of the maximal tolerated allergen dose will help us to further improve epicutaneous allergen immunotherapy, which has the potential to make allergen specific immunotherapy not only considerably shorter and safer, but also more convenient for patients. Skin preparation by microneedle patches is significantly less painful than conventional injection and can be self administered. This should help improve the acceptance of allergen specific immunotherapy, as well as treatment compliance.
Detailed description
BACKGROUND INFORMATION The prevalence of allergic diseases has been continuously increasing, reaching a prevalence of up to 30% in industrialized countries. In Switzerland, about 2 million people are affected by IgE-mediated allergies as reported by the Swiss Center for Allergy, Skin and Asthma and the Swiss Society for Allergology and Immunology (SSAI). By subcutaneous injections of gradually increasing allergen doses, conventional subcutaneous SIT (SCIT) is found to reduce the inappropriate T-helper (Th) 2 responses and IgE production. Due to the risk of systemic allergic side effects, the typical therapy duration of 3-5 years and the requirement of 50-80 injections, patient acceptance of SCIT is low and less than 5% of allergy patients choose to undergo SCIT. A recently rediscovered route of allergen administration is via the epidermis in a procedure called epicutaneous immunotherapy (EPIT).
The skin is an attractive administration route for immunotherapy being both easily accessible as well as playing an important role in the immune system consisting of keratinocytes, Langerhans cells (LC), dermal dendritic cells (DC). A major challenge in EPIT is to overcome the physiological barrier function of the skin. In order to deliver the allergen to the immunological effector cells in the skin, the allergen must be transported through the outermost keratinized layer of the epidermis, called the stratum corneum. The stratum corneum is 10-20μm thick and impermeable for molecules greater than 500 Da. Proteins, such as allergens, do not passively permeate across the skin and therefore enhancement strategies are needed to enable this transfer. Advances in microtechnology might contribute to improve the situation by allowing for the miniaturization of mechanics and structures. As the stratum corneum is only 10-20μm thick, it has been proposed by Henry et al., that microneedles as small as a few tens to a few hundreds of microns, could be used to penetrate the stratum corneum.
Such new methods of overcoming the skin barrier raise the question of the influence of different types of skin injury patterns on the allergic skin reactivity. Namely, how important is the role of the exposed area (microneedles), the depth of injury (skin pricking) and the keratinocyte activation. This physiological question is in the focus of this study.
PRODUCTS In order to investigate the physiological reactions concerning different skin conditions and allergen exposition the following products/techniques have been chosen for the purpose of inducing different skin conditions in a reproducible way.
Prick lancet:
For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used: prick lancet, produced by Entaco LTD., Redditch, Worcestershire, UK and distributed by Stallergenes®. They are used for allergy diagnostics in daily routine.
Adhesive tape:
For the tape stripping skin preparation a conventional tape will be used (Tesafilm®).
Microneedle array:
To induce a large number of microchannels with a maximal depth of 150μm into the cornea layer,the solid Microstructured Transdermal System (sMTS) by 3M® will be used. This system is a small patch of 351 tiny needles, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
Epicutaneous allergen solution:
For the epicutaneous administration four ten-fold serial dilutions (10 HEP, 1 HEP, 0.1 HEP and 0.01HEP/ml) of registered allergen extracts of birch pollen (Betula verrucosa) (Soluprick®, ALK-Abelló A/S, Hørsholm, Denmark) will be used as in everyday allergy diagnostic practice. Histamine as positive control will be used at 10 mg/ml and a solution containing only the excipients will serve as negative control.
This is an open-label physiological investigation of the allergic skin reactivity to epicutaneous allergen exposition in allergic patients comparing different methods of skin preparation. The focus of the study is on the skin preparation and not on the specific allergen or allergy, but for reasons of homogeneity a single allergic disease, birch pollen allergy was chosen as the basis for the testing. In order to evaluate the effects of the different skin preparation techniques an intra-individual comparison of the skin reactivity in terms of the immediate phase I reaction to serial dilutions of birch pollen extracts was chosen. The serial dilution approach allows a dose dependent effect evaluation and determination of the mean allergen concentration yielding similar skin reactions - thus differences will be explained mainly by the different skin preparation allowing a quantitative comparison of these techniques.
HYPOTHESIS We will determine which of the three different skin preparation techniques uses higher protein concentration of allergen preparation (Ch10) eliciting a wheal area of the same size as histamine 10 mg/ml will be calculated.
The Null hypothesis therefore would be:
Ch10 is not significantly different between the three skin preparation techniques.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Skin Preparation Testing | Other | Other: prick lancet, Other: Tape stripping, Other: MicroneedleThe methodology of this study is an intra-individual comparison. Each study participant is treated with three skin preparation techniques (pricking, tape stripping, microneedle array)on both volar forearms. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Written informed consent
- 18-65 years old (male and female)
- A positive clinical history for inhalant allergy presumably due to birch pollen
- Positive screening prick test (mean wheal diameter = 3mm) to birch pollen allergen solution
- A mean wheal size of = 7mm2 obtained in the screening prick test with histamine dihydrochloride (10mg/ml)
Key exclusion criteria (11 listed)
- Impaired in understanding the nature, meaning and scope of the study or incapable of giving written informed consent
- Participation in another clinical trial within the last 30 days and during the present study
- Pregnancy or nursing
- Positive skin reaction in the screening prick test to NaCl
- Currently suffering from allergy symptoms
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| prick lancetAlso: Prick Lancet; Worcestershire, UK; distr. by Stallergenes®.For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine. | Other | Skin Preparation Testing |
| Tape strippingAlso: TesafilmFor the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used. | Other | Skin Preparation Testing |
| MicroneedleAlso: solid Microstructured Transdermal System (sMTS) by 3M®To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products. | Other | Skin Preparation Testing |
Primary outcome
Wheal size of the immediate reaction in mm2.
Time frame: 15 minutes
1 secondary outcome
Late phase response.
Time frame: 3 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Nov 2012.
Related trials for Birch Pollen Allergy
Not yet recruitingPhase 1
Safety, Tolerability And Pharmacodynamics of DM-101PX in Birch Pollen Allergy
Birch Pollen Allergy
Not yet recruitingObservational study
A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy
Conjunctivitis Allergic
RecruitingPhase 3
Evaluation of the Efficacy of Oral Immunotherapy With Raw Apple in Patients Allergic to Birch Pollen and Apple: Prospective, Multicenter, Comparative Phase III Study
Allergies
Not yet recruitingObservational study
Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects
Allergic Rhinitis, Allergic Conjunctivitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thomas Kuendig, MD principal investigator
University Hospital Zurich, Division of Dermatology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing prick lancet, Tape stripping and Microneedle in people with Birch Pollen Allergy, run by University of Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Nov 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Wheal size of the immediate reaction in mm2. (time frame: 15 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2012.